Acute Liver Failure
Acute liver failure is a sudden, severe liver dysfunction characterized by hepatic encephalopathy and impaired protein synthesis in individuals without preexisting liver disease, commonly caused by hepatitis viruses or drugs like acetaminophen. Classified by onset speed—hyperacute (within 1 week), acute (8–28 days), and subacute (4–12 weeks)—this condition signals severe liver damage and its outcomes are highly influenced by both the rapidity of onset and underlying cause.
Health Outcomes
- Absence of Bacterial Translocation to Liver or Spleen
- Alleviated Organ Injury
- Alleviated Symptoms in Acetaminophen-Induced Model
- Altered Liver Biomarker Level
- Altered Plasma Metabolite Levels
- Changed Alanine Aminotransferase Level
- Changed Albumin Level
- Changed Alkaline Phosphatase Level
- Changed Clinical Chemistry Measure
- Elevated Acetic Acid Levels
- Elevated Lactate Levels
- Elevated Serum Enzyme Levels
- Enhanced Active Metabolite Levels
- Enhanced Antioxidant Metabolism
- Improved Acute Liver Injury
- Improved Alanine Aminotransferase Level
- Improved Alcohol-Associated Liver Disease Parameters
- Improved Bilirubin Level
- Improved Detoxification Pathway
- Improved Enzyme Levels (ADH, ALDH)
- Improved Hepatic Damage
- Improved Hepatic Function
- Improved Hepatic Marker
- Improved Liver Enzyme Level
- Improved Liver Function
- Improved Liver Function (AST)
- Increased Alkaline Phosphatase Activity in Skin Mucus
- Increased Alkaline Phosphatase Level
- Increased Anion Gap
- Increased Aspartate Aminotransferase Concentration
- Increased Aspartate Transferase Level
- Increased Cellular Apoptosis
- Increased Conjugated Bile Acid Levels
- Increased Enzyme Production
- Increased Hepatic Glutathione Content
- Increased Lactic Acid Levels
- Increased Liver Enzyme Levels
- Increased PT/INR
- Increased Plasma GLDH
- Increased Vitamin K Level
- Induced Apoptosis
- Liver Protection from Aflatoxin B1 Damage
- Maintained Safety with Repeated Oral Exposure
- No Illness or Death from Bacterial Translocation (Intraperitoneal Administration)
- No Long-Term Impact on Gut Microbiota
- Normal Safety Parameters
- Normalized INR
- Prolonged INR
- Reduced Abnormal Increase in Bilirubin
- Reduced Acetaminophen Intake
- Reduced Acetaminophen Use
- Reduced Ammonia Excretion
- Reduced Ammonia Levels
- Reduced Anticoagulation / Increased Warfarin Variability
- Reduced Apolipoprotein B Level
- Reduced Aspartate Transaminase Activity
- Reduced Butyrylcholinesterase Activity
- Reduced Child-Pugh Score
- Reduced Cholic Acid Level
- Reduced Coagulation Marker Level
- Reduced Cytotoxicity
- Reduced Ferroptosis
- Reduced Fresh Frozen Plasma Transfusion
- Reduced GPT Level
- Reduced Glutamyl Pyruvic Transaminase Levels
- Reduced Hepatic Damage Indices
- Reduced Hepatic Encephalopathy
- Reduced Hepatic Enzyme Level
- Reduced Indirect Bilirubin Level
- Reduced Isoleucine Level
- Reduced Jaundice Duration
- Reduced Life Threatening Complication
- Reduced Liver Damage
- Reduced Liver Enzyme Activity
- Reduced Liver Function
- Reduced Liver Function Indicators
- Reduced Liver Injury
- Reduced Liver Injury Marker
- Reduced Liver Transplantation Requirement
- Reduced MELD Score
- Reduced Methylphenidate Dosing Requirement
- Reduced Need for Continuous Renal Replacement Therapy
- Reduced Organ Dysfunction
- Reduced Organ Dysfunction Severity
- Reduced Organ Failure Severity
- Reduced Organ Injury
- Reduced PIVKA-II Concentration
- Reduced Plasma Urea Level
- Reduced Prothrombin Level
- Reduced Prothrombin Time
- Reduced Scleral Icterus Duration
- Reduced Sequential Organ Failure Assessment Score
- Reduced Short-term Mortality
- Reduced Urea Level
- Reduced Vitamin K Deficiency Bleeding Incidence
- Shortened Oliguria Period
- Stabilized Total Bilirubin Levels